Orthostatic Grading Scale (OGS)
Five questions grading how much standing up costs you, scored 0–20
The Orthostatic Grading Scale was developed at the Mayo Clinic's autonomic laboratory by Schrezenmaier, Low, Sandroni and colleagues and published in 2005. It was designed to put a number on orthostatic intolerance in the way a clinician would take a history: how often symptoms happen on standing, how severe they are, what conditions bring them on, how much they interfere with daily activities, and how long you can stand before they start. Each of the five items scores 0–4, for a total of 0–20.
In the original study of 145 patients the scale was internally consistent (alpha 0.91) and tracked laboratory measures of adrenergic autonomic function. It has since been used in UK POTS research, ME/CFS studies, the CDC's multi-site ME/CFS study, and post-COVID cohorts. "Orthostatic symptoms" here means the symptoms you get on standing: lightheadedness, dizziness, blurred vision, weakness, fatigue, brain fog, palpitations, nausea, or feeling faint.
The OGS describes your usual pattern, which makes it a good baseline and monthly tracking measure. The Vanderbilt Orthostatic Symptom Score is the complementary snapshot rated while standing, the Malmö POTS score covers the past week, and the NASA lean test records the heart-rate data that a POTS or orthostatic hypotension diagnosis actually needs.
Your Orthostatic Grading Scale score
Item breakdown
Reference values
Average totals in published studies; sources are listed under "Understanding your OGS score" below.
Your results over time
Complete this again in a few weeks and the change will show here.
Symptom scores change slowly. A monthly retake is enough to see a trend.
Your results are stored only in this browser, on this device. Nothing is sent to us or to anyone else. They will be lost if you clear this site's data, use a private window, or switch browser or device. You can delete them at any time.
Understanding your OGS score
What the score measures
The Orthostatic Grading Scale (OGS) is a five-question self-report scale from the Mayo Clinic, published in 2005. It asks how often you get symptoms on standing, how severe they are, what brings them on, how much they interfere with daily life and how long you can stand. Each question scores 0 to 4, giving a total from 0 to 20. Higher means more orthostatic symptoms.
In the original study of 145 people tested in the Mayo autonomic laboratory, the five questions hung together well (alpha 0.91), and scores tracked laboratory measures of autonomic function, most closely the adrenergic (blood pressure control) part (Schrezenmaier et al. 2005).
Yes. It was designed for symptoms of low blood pressure on standing, but a 2023 study of 149 people being investigated for POTS found that its five questions measure a single underlying problem and that scores rose modestly with heart rate on standing. UK POTS patients have averaged 13. (Knoop et al. 2023)
Score bands
Studies using the OGS treat 4 or more as consistent with orthostatic intolerance and 9 or more as consistent with orthostatic hypotension, citing the original Mayo paper. Neither threshold is a diagnosis. For comparison, published averages are 0.6 in healthy controls, 8.3 in ME/CFS and 13 in POTS.
The thresholds of 4 and 9 are as stated by Słomko et al. 2020; we could not check them against the full text of the original paper. Mild, moderate and severe labels sometimes quoted for the OGS have no published thresholds we could verify, so they are not used here.
| Group | People | Average | Source |
|---|---|---|---|
| Healthy controls (US) | 141 | 0.6 | Issa et al. 2025 |
| Hypermobility spectrum disorder (Australia) | 15 | 6.8 | Peebles et al. 2022 |
| ME/CFS (US) | 301 | 8.3 | Issa et al. 2025 |
| Hypermobile EDS (Australia) | 14 | 10.4 | Peebles et al. 2022 |
| Long COVID (Spain) | 23 | 10.6 | Domingo et al. 2024 |
| ME/CFS (Spain) | 31 | 12.8 | Domingo et al. 2024 |
| POTS (UK) | 136 | 13 | McDonald et al. 2014 |
What a change in score means
No minimal important change has been published. The OGS asks about your usual pattern rather than one day, so it changes slowly. Repeat it monthly or around a treatment change; a shift that holds over several results is more likely to be real than a one-off difference.
Your saved results above keep the history on this device; keep your stand test readings alongside.
What it does not measure
No. It measures the burden of symptoms on standing, whatever the cause. POTS and orthostatic hypotension are diagnosed from heart rate and blood pressure measured lying and then standing or tilted. A high score is a reason to ask for that testing.
The NASA lean test records those readings at home, and the 30 bpm threshold explainer covers what they mean. The Malmö POTS score covers a wider set of symptoms over the past week.
Taking this to your GP or consultant
Bring your total, the date, your answer to the standing-time question and, if you have it, the trend from your saved results. Describe the OGS as a five-question Mayo Clinic scale for symptoms on standing, used in POTS and ME/CFS research. A score of 9 or more, with symptoms on standing, supports asking for a lying and standing blood pressure and heart rate check. It does not show what is causing the symptoms. See preparing for a GP appointment.
Sources
- Schrezenmaier C, Gehrking JA, Hines SM, Low PA, Benrud-Larson LM, Sandroni P. Evaluation of orthostatic hypotension: relationship of a new self-report instrument to laboratory-based measures. Mayo Clin Proc 2005;80(3):330–334. Article
- Słomko J, et al. Autonomic phenotypes in chronic fatigue syndrome (CFS) are associated with illness severity: a cluster analysis. J Clin Med 2020;9(8):2531. Full text
- Knoop I, et al. Validation of symptom measures in patients under investigation for postural orthostatic tachycardia syndrome (POTS): the Orthostatic Grading Scale (OGS) and the Symptom Screen for Small-fiber Polyneuropathy (SSS). Auton Neurosci 2023. Article
- Issa A, et al. Autonomic dysfunction in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): findings from the Multi-Site Clinical Assessment of ME/CFS (MCAM) study in the USA. J Clin Med 2025;14(17):6269. Full text
- Peebles KC, et al. The prevalence and impact of orthostatic intolerance in young women across the hypermobility spectrum. Am J Med Genet A 2022;188(6):1761. Full text
- McDonald C, Koshi S, Busner L, Kavi L, Newton JL. Postural tachycardia syndrome is associated with significant symptoms and functional impairment predominantly affecting young women: a UK perspective. BMJ Open 2014;4:e004127. Full text
- Domingo JC, et al. Association of circulating biomarkers with illness severity measures differentiates myalgic encephalomyelitis/chronic fatigue syndrome and post-COVID-19 condition: a prospective pilot cohort study. J Transl Med 2024;22:343. Full text